NASDAQ:GANX Gain Therapeutics Q3 2025 Earnings Report $1.68 -0.09 (-5.08%) Closing price 09/29/2026 04:00 PM EasternExtended Trading$1.70 +0.03 (+1.49%) As of 09:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Gain Therapeutics EPS ResultsActual EPS-$0.15Consensus EPS -$0.15Beat/MissMet ExpectationsOne Year Ago EPSN/AGain Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AGain Therapeutics Announcement DetailsQuarterQ3 2025Date11/12/2025TimeBefore Market OpensConference Call DateWednesday, November 12, 2025Conference Call Time7:00AM ETUpcoming EarningsGain Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Gain Therapeutics Earnings HeadlinesGain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement DisordersSeptember 29 at 10:32 PM | markets.businessinsider.comGain Therapeutics Announces Poster Presentation at International Congress of Parkinson's Disease and Movement DisordersSeptember 29 at 6:00 PM | globenewswire.comTrump Wants to Reprice America's Gold at Market ValueThe US government still values its gold reserves at 42 dollars an ounce, a price Congress set in 1973. Gold trades above 4000 today, leaving official books showing about 11 billion dollars for holdings worth more than 1 trillion in the real market. A bill now moving through Congress would require the Treasury to reprice that gold at current market value, while companion legislation could trigger the first audit of US gold holdings in more than 65 years. More than 60 million Americans qualify to move part of their savings into physical gold, tax-free and penalty-free.September 30 at 1:00 AM | Concord Gold Capital (Ad)Comparing Spyre Therapeutics (NASDAQ:SYRE) and Gain Therapeutics (NASDAQ:GANX)September 28 at 8:14 AM | americanbankingnews.comGain Therapeutics Announces CEO Gene Mack to Participate in ROTH Healthcare Opportunities Conference Panel and One-on-One MeetingsSeptember 17, 2026 | quiverquant.comQGain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities ConferenceSeptember 17, 2026 | globenewswire.comSee More Gain Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Gain Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gain Therapeutics and other key companies, straight to your email. Email Address About Gain TherapeuticsGain Therapeutics (NASDAQ:GANX) is a clinical-stage biotechnology company focused on developing small-molecule therapies for neurodegenerative diseases and lysosomal storage disorders. The company’s research is directed at restoring the function of misfolded or dysfunctional proteins that contribute to disease progression. Gain Therapeutics uses its proprietary SEE-Tx drug-discovery platform to identify previously unrecognized allosteric binding sites on proteins and develop compounds designed to stabilize or reactivate those proteins. Its lead program, GT-02287, is an orally administered small molecule being studied for Parkinson’s disease, including disease associated with mutations in the GBA1 gene. The company was founded in 2017 and has pursued development through clinical-stage programs supported by preclinical research in neurodegenerative disease. Gain Therapeutics is headquartered in the United States and trades on the Nasdaq Capital Market under the symbol GANX.View Gain Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles CarMax Just Gave Investors a Better Reason to Believe in the TurnaroundBernstein Downgrades 3 Cybersecurity Stocks: How Concerned Should Investors Be?Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks3 Stocks Under the Microscope After Large Insider Sales3 Healthcare Stocks Showing Why the Sector Still Has Momentum Upcoming Earnings NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
